Sonoma Pharmaceuticals, Inc. (SNOA)

Market Cap	6.05M
Revenue (ttm)	14.29M
Net Income (ttm)	-3.46M
Shares Out	1.64M
EPS (ttm)	-2.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,499
Open	3.660
Previous Close	3.680
Day's Range	3.540 - 3.860
52-Week Range	1.750 - 9.000
Beta	1.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2025

About SNOA

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 25, 2007
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: SNOA
• Website: https://sonomapharma.com

Financial Performance

In 2024, Sonoma Pharmaceuticals's revenue was $14.29 million, an increase of 12.19% compared to the previous year's $12.74 million. Losses were -$3.46 million, -28.50% less than in 2023.